Multiple Myeloma Therapeutics Market – Global Analysis and Forecast 2014-2024

The global multiple myeloma therapeutics market was valued at USD 7.5 billion in 2015 and is expected to reach a value of USD 37.5 billion by 2024. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.

This space is expected to gain momentum with the addition of novel drugs to the current therapeutics array with monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatis faction and increase life expectancies of patients; which in turn is expected to boost the research and development of improved therapies for multiple myeloma.

Growing prevalence of the disease along with the surging elderly population is the prime factor expected to drive the growth significantly during the forecast period. Complications involved in treating geriatric patients are driving the demand for supportive treatments such as restoration procedures involving transfusion of blood components and point of care technologies.

The U.S, followed by Europe, has been dominating the market owing to the presence of major players in these regions, faster approval rates, and favorable healthcare policies. Higher prevalence of multiple myeloma in the developed economies is a pivotal determinant driving the growth of the Europe market.

The space consists of a few major players including Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, and Novartis AG. A large revenue share is captured by Celgene Corporation with its high-performing drug, Revlimid. The drug currently dominates the market with more than 50% share of the total multiple myeloma therapeutics market.

To request a sample copy or view summary of this report: 
http://www.grandviewresearch.com/industry-analysis/multiple-myeloma-therapeutics-market


Further Key Findings from the Study Suggest:

• According to the National Cancer Institute, more than 30,330 new cases of multiple myelomaare expected to register in 2016. The number of new cases is expected to grow each year with the growing geriatric population.
• Newly introduced drugs are expected to increase the longevity of patients undergoing treatment for multiple myeloma, which yields a high cumulative number of patients requiring treatment each year.
• In 2015, the chemotherapy and other drugs segment dominated the global space with largest revenue share owing to lack of effective alternative option.
• Chemotherapy and other drugs segment has been sub-segmented into traditional chemotherapy, immunomodulating agents, protea some inhibitors, HDAC inhibitors, and monoclonal antibodies.
• In 2015, immunomodulating agents drug class captured the largest market share. Absence of comparable alternatives is the prime factor driving the growth of the segment
• The newly introduced drugs belonging to the classes HDAC inhibitors and monoclonal antibodies are expected to show the fastest growth during the forecast period owing to the effectiveness and safety of these drugs

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-multiple-myeloma-therapeutics-market

Market Outlook of Global Healthcare CRM Market Analysis and Foresight Report to 2025

The global healthcare CRM market is expected to reach USD 17.4 billion by 2025, according to a new study by Grand View Research Inc. Rising demand for workflow automation and single platform for tracking medical information provides coordination of patient care, service and timely delivery which is expected to drive the industry growth.

The healthcare payers, providers and life science companies also need better integration between their administration and patient queries which is further anticipated to increase the market growth. The healthcare payers, providers and life science companies also need better integration between their administration and patient queries which is further anticipated to increase the market growth.

Gathering information about target customers, marketing effectiveness, sales, feedback and market needs facilitates the workflow automation within the organization which is another vital factor leading towards the growth of the healthcare customer relationship management market. Moreover, technological advancements in cloud CRM, mobile CRM and social CRM provides effective communication medium which is expected to further accelerate healthcare customer relationship management industry growth.

Gathering information about target customers, marketing effectiveness, sales, feedback and market needs facilitates the workflow automation within the organization which is another vital factor leading towards the growth of the healthcare CRM market. Moreover, technological advancements in cloud CRM, mobile CRM and social CRM provides effective communication medium which is expected to further accelerate healthcare CRM industry growth.

To request a sample copy or view summary of this report:
http://www.grandviewresearch.com/industry-analysis/crm-in-healthcare-market

Further key findings from the study suggest:

• Cloud CRM is identified as the largest technology segment used as platform for the healthcare CRM industry owing to, rising need for accessing the software from different devices and locations.
• Mobile customer relationship management segment is expected to be the fastest growing technology segment with a lucrative CAGR over the forecast period.
• Hybrid of individual and referral CRM system is expected to be the largest product segment by 2025 owing to the advantages of both the models in getting access to sensitive patient information.
• Referral healthcare CRM is expected to be the fastest growing product segment over the forecast period.
• Key market players for healthcare CRM include IBM, salesforce.com, Veeva Systems, Siemens Healthcare, SAP, Accenture, Oracle, Microsoft, Amdocs Ltd., Anthelio Healthcare Solutions, AllScripts Healthcare Solutions Inc., NetSuite, Cerner, Nice systems, Talisma, Lawson and Verint Systems.

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-healthcare-crm-customer-relationship-management-market

Market Outlook of Global Healthcare CRM Market Analysis and Foresight Report to 2025

The global healthcare CRM market is expected to reach USD 17.4 billion by 2025, according to a new study by Grand View Research Inc. Rising demand for workflow automation and single platform for tracking medical information provides coordination of patient care, service and timely delivery which is expected to drive the industry growth.

The healthcare payers, providers and life science companies also need better integration between their administration and patient queries which is further anticipated to increase the market growth. The healthcare payers, providers and life science companies also need better integration between their administration and patient queries which is further anticipated to increase the market growth.

Gathering information about target customers, marketing effectiveness, sales, feedback and market needs facilitates the workflow automation within the organization which is another vital factor leading towards the growth of the healthcare customer relationship management market. Moreover, technological advancements in cloud CRM, mobile CRM and social CRM provides effective communication medium which is expected to further accelerate healthcare customer relationship management industry growth.

Gathering information about target customers, marketing effectiveness, sales, feedback and market needs facilitates the workflow automation within the organization which is another vital factor leading towards the growth of the healthcare CRM market. Moreover, technological advancements in cloud CRM, mobile CRM and social CRM provides effective communication medium which is expected to further accelerate healthcare CRM industry growth.

To request a sample copy or view summary of this report: 
http://www.grandviewresearch.com/industry-analysis/crm-in-healthcare-market

Further key findings from the study suggest:

• Cloud CRM is identified as the largest technology segment used as platform for the healthcare CRM industry owing to, rising need for accessing the software from different devices and locations.
• Mobile customer relationship management segment is expected to be the fastest growing technology segment with a lucrative CAGR over the forecast period.
• Hybrid of individual and referral CRM system is expected to be the largest product segment by 2025 owing to the advantages of both the models in getting access to sensitive patient information.
• Referral healthcare CRM is expected to be the fastest growing product segment over the forecast period.
• Key market players for healthcare CRM include IBM, salesforce.com, Veeva Systems, Siemens Healthcare, SAP, Accenture, Oracle, Microsoft, Amdocs Ltd., Anthelio Healthcare Solutions, AllScripts Healthcare Solutions Inc., NetSuite, Cerner, Nice systems, Talisma, Lawson and Verint Systems.

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-healthcare-crm-customer-relationship-management-market 

Biosensors Finds Application in Medical Devices - Trends & Forecast by 2020

Global Biosensors Market is expected to reach USD 21.17 billion by 2020, according to a new study published by Grand View Research, Inc. Biosensors, owing to their capability to resolve various analytical issues in diverse areas such as medicine, pharmacology, food & agriculture safety and defense, are expected to witness a rapid growth in demand over the next six years. Increasing demand for specific detection techniques for early diagnosis in the healthcare sector is expected to drive the overall biosensors market during the forecast period. Furthermore, the expanding role of biosensors in the real world environment has led to a hike in R&D efforts globally.

Browse Full research report on Biosensors Market Analysis:
http://www.grandviewresearch.com/industry-analysis/biosensors-market

Further key findings from the study suggest:

• Optical biosensors are identified as the most lucrative technology segment of this market and are expected to grow at a CAGR of over 7.0% during the forecast period. Growing use of these sensors in the field of environmental scanning is one of the key drivers of this market. The recent progress in optical biosensors has made them apt for environmental scanning wherein they are used for quantifying and characterizing environmental pollutants.
• Biosensors are mostly used in devices enabled with point of care testing. The biosensors based point of care testing segment accounted for over 40% of the end-use market in 2013. Moreover, rising demand for portable and integrated technologies that can be operated by untrained personnel outside conventional laboratories is expected to improve usage rates.
• North America accounted for more than 35% of the market in 2013. Biosensors witness the highest market penetration rates in this region owing to the presence of high procedure volumes supported by favorable government initiatives. Moreover, rapidly growing demand for point of care and home healthcare markets in the U.S. is expected to drive regional market growth during the forecast period.
• Asia Pacific has high future growth potential owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives aimed at improving environmental conditions and enhancing healthcare infrastructure in Japan and Australia are also expected to serve as a high impact rendering driver for this market.
• Key players of this market include Abbott Point of Care Inc., Roche, Lifescan Inc., Bayer AG, Medtronic Inc., Universal Biosensors, Siemens Healthcare and Nova Biomedical Corporation.

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-biosensors-market

Bioinformatics Market are Good Investment for Business in Upcoming Years

The global bioinformatics market is expected to reach USD 13.47 billion by 2020 growing at an estimated CAGR of 21.2% from 2014 to 2020, according to a new report by Grand View Research, Inc. Growing clinical development of biopharmaceutical and increasing need for three dimensional drug designing technology are expected to drive the market growth over the next five years.

Further development of bioinformatics tools, platforms and analysis platforms coupled with the introduction of novel technologies are expected to be high impact rendering factors for the growth of this market. Increasing demand for faster development of novel API and biopharmaceuticals is also expected to enhance the growth of this industry.

To request a sample copy or view summary of this report: 
http://www.grandviewresearch.com/industry-analysis/bioinformatics-industry

Growth in the number of research and development studies in various ‘omics’ related segments and need for integration of the large amounts of biological data generated from these studies is also expected to encourage industry players to develop faster, more efficient and versatile bioinformatics software cum platforms for commercialization.

Bio-content processing accounted for over 47% of the revenue share in 2013. The presence of increasing market demand for genetic databases management, and need for related sequence, structural and phylogenic analysis tools and software is the primary factor accounting for this large share.

Moreover, the sequence and structural analysis platform segment is expected to grow at the fastest CAGR of over 20% over the forecast period owing to the development of next generation sequencing and expected reduction in cost of whole genome exome sequencing. These factors are expected to have a significantly positive impact on the overall growth of this market in the next five years.

Chemo-informatics and genomics accounted for over 50% of revenue share in 2013. Growing demand for novel biomarkers for R&D of biosimilar drugs and biopharmaceuticals is expected to significantly enhance the market penetration over the forecast period.

Proteomic applications are expected to attract a considerable amount of R&D investment in the near future and witness a lucrative growth over the forecast period. Developments in three dimensional drug development technologies are further expected to boost the growth of this segment.

North America was observed to account for over 40% of the global revenue in 2013. Factors accounting for this large share include the presence of large pharmaceutical companies in the region, which are involved in the clinical development of novel APIs and biosimilar drugs. The presence of a technologically advanced healthcare R&D framework also enhances this region’s investment capabilities for the development of the aforementioned market segments.

Asia Pacific is expected to grow at the fastest CAGR over the forecast period owing to the presence of companies providing outsourcing services to the industry for larger eastern industry players. Furthermore, the presence of high unmet industry need is also expected to be significant reason to impact the growth of this region positively over the forecast period.

Key players in this industry include IBM Life Sciences, BIOVIA, Life Technologies Corporation, Agilent technologies, 3rdMillennium Inc., Celera Corporation, Affymetrix, BioWisdom Ltd., and Rosetta Biosoftware.

Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-bioinformatics-market